

Yair Lotan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/331183/publications.pdf>

Version: 2024-02-01

595
papers

37,352
citations

3158

92
h-index

4645

170
g-index

622
all docs

622
docs citations

622
times ranked

25630
citing authors

#	ARTICLE	IF	CITATIONS
1	The Search for the Optimal cut-off Value of p53-Immunohistochemistry to Predict Prognosis of Invasive Bladder Cancer: A Multi-Center, Multi-Laboratory Analysis. <i>International Journal of Surgical Pathology</i> , 2023, 31, 157-166.	0.8	1
2	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 85-95.	4.2	6
3	Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 9.e19-9.e27.	1.6	5
4	Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2022, 207, 70-76.	0.4	15
5	Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System. <i>Journal of Urology</i> , 2022, 207, 52-60.	0.4	5
6	Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. <i>Journal of Urology</i> , 2022, 207, 534-540.	0.4	4
7	Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2022, 207, 541-550.	0.4	30
8	Role of blue light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry. <i>BJU International</i> , 2022, 130, 62-67.	2.5	6
9	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 3091-3102.	2.5	2
10	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>European Urology Focus</i> , 2022, 8, 972-979.	3.1	3
11	Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 779182.	2.8	0
12	TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. <i>European Urology Oncology</i> , 2022, 5, 714-718.	5.4	32
13	Actionable genomic landscapes from a real-world cohort of localized urothelial carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 525-525.	1.6	0
14	PD-L1 expression and BCG response in nonmuscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 545-545.	1.6	3
15	Outcomes of patients undergoing concurrent radical cystectomy and nephroureterectomy: A single-institution series. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.6	5
16	VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 488-488.	1.6	2
17	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	1.6	22
18	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, 29, 5307-5316.	1.5	6

#	ARTICLE	IF	CITATIONS
19	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. <i>European Urology</i> , 2022, 81, 223-228.	1.9	8
20	Prognostic impact of insulin-like growth factor and its binding proteins, insulin-like growth factor binding protein 2 and 3, on adverse histopathological features and survival outcomes after radical cystectomy. <i>International Journal of Urology</i> , 2022, , .	1.0	3
21	Predictive factors of diagnostic delay and effect on treatment patterns in testicular germ cell tumor patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 201.e1-201.e7.	1.6	3
22	International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2022, 82, 34-46.	1.9	30
23	Progress in the development of tissue-based biomarkers for urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 605-619.	2.4	1
24	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
25	Safety and Feasibility of Telehealth Only Preoperative Evaluation Before Minimally Invasive Robotic Urologic Surgery. <i>Journal of Endourology</i> , 2022, 36, 1070-1076.	2.1	4
26	Outcomes of Patients with Bacillus Calmette-Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer as Defined by the U.S. Food and Drug Administration. <i>Bladder Cancer</i> , 2022, , 1-12.	0.4	0
27	Lipidomic Profiling Identifies a Novel Lipid Signature Associated with Ethnicity-Specific Disparity of Bladder Cancer. <i>Metabolites</i> , 2022, 12, 544.	2.9	2
28	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 382.e1-382.e6.	1.6	3
29	Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis. <i>BJU International</i> , 2021, 128, 79-87.	2.5	10
30	Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. <i>World Journal of Urology</i> , 2021, 39, 1977-1984.	2.2	9
31	Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. <i>BJU International</i> , 2021, 128, 168-177.	2.5	15
32	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. <i>World Journal of Urology</i> , 2021, 39, 491-500.	2.2	2
33	Robotic Nephroureterectomy vs Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. <i>Journal of Endourology</i> , 2021, 35, 312-318.	2.1	18
34	Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. <i>BJU International</i> , 2021, 127, 108-113.	2.5	11
35	Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma. <i>BJU International</i> , 2021, 127, 528-537.	2.5	10
36	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. <i>Lancet Oncology</i> , The, 2021, 22, 107-117.	10.7	172

#	ARTICLE	IF	CITATIONS
37	Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. <i>European Urology Oncology</i> , 2021, 4, 93-101.	5.4	25
38	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. <i>BJU International</i> , 2021, 127, 617-625.	2.5	13
39	Using Urinary Biomarkers in Urothelial Carcinoma of the Bladder and Upper Tracts. , 2021, , 21-31.		0
40	Decision Analysis Model Comparing Cost of IsoPSA vs Repeat Biopsy for Detection of Clinically Significant Prostate Cancer in Men with Previous Negative Findings on Biopsy. <i>Urology Practice</i> , 2021, 8, 40-46.	0.5	1
41	Bladder Cancer Tissue-Based Biomarkers. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, 53-71.	0.4	0
42	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. <i>Journal of Urology</i> , 2021, 205, 137-144.	0.4	28
43	Validation of testicular germ cell tumor (GCT) staging in nationwide cancer registries.. <i>Journal of Clinical Oncology</i> , 2021, 39, 383-383.	1.6	0
44	Survival by T Stage for Patients with Localized Bladder Cancer: Implications for Future Screening Trials. <i>Bladder Cancer</i> , 2021, 7, 23-31.	0.4	2
45	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 769-779.	0.4	45
46	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 779-779.	0.4	1
47	MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 628094.	2.8	12
48	Simple Nephrectomy in a Tertiary Care Safety Net Hospital� Patient Characteristics, Causes, Cost, and Renal Function Implications. <i>Urology</i> , 2021, 149, 98-102.	1.0	2
49	Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 787.e1-787.e7.	1.6	6
50	Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens. <i>Oncotarget</i> , 2021, 12, 783-790.	1.8	4
51	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>European Urology Open Science</i> , 2021, 26, 83-87.	0.4	26
52	Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert [�]) Tj ETQq0 0 0 rgBT /Overlock International, 2021, 128, 713-721.	2.5	16
53	Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria. <i>Journal of Urology</i> , 2021, 205, 1387-1393.	0.4	11
54	Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. <i>Journal of Endourology</i> , 2021, 35, 647-651.	2.1	4

#	ARTICLE	IF	CITATIONS
55	The Economics of Cystoscopy: A Microcost Analysis. <i>Urology</i> , 2021, 157, 29-34.	1.0	10
56	Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. <i>Clinical Cancer Research</i> , 2021, 27, 5123-5130.	7.0	65
57	Metabolic syndrome and bladder cancer. <i>BJU International</i> , 2021, 128, 1-2.	2.5	5
58	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. <i>Journal of Urology</i> , 2021, 206, 1122-1131.	0.4	5
59	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e1-790.e7.	1.6	10
60	Risk factors associated with positive surgical margins™ location at radical cystectomy and their impact on bladder cancer survival. <i>World Journal of Urology</i> , 2021, 39, 4363-4371.	2.2	22
61	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 409-421.	1.6	17
62	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , 2021, 80, 149-159.	1.9	17
63	A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2021, 7, 285-295.	0.4	2
64	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	2.2	4
65	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. <i>Cancers</i> , 2021, 13, 4378.	3.7	35
66	Same Day Discharge Versus Overnight Observation Protocols – Similar Outcomes Following Artificial Urinary Sphincter Surgery. <i>Urology</i> , 2021, 157, 206-210.	1.0	2
67	Alternating Cystoscopy with Bladder EpiCheck® in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021, 7, 307-315.	0.4	3
68	The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 206, 1380-1389.	0.4	8
69	A Multi-Institutional Phase 2 Trial of High-Dose SABR for Prostate Cancer Using Rectal Spacer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 101-109.	0.8	19
70	Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 734.e11-734.e17.	1.6	4
71	Re: ctDNA Guiding Adjuvant Immunotherapy in Urothelial Carcinoma. <i>European Urology</i> , 2021, 80, 517-518.	1.9	2
72	The early impact of medicaid expansion on urologic malignancies in the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 103.e1-103.e1.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Validation of testicular germ cell tumor staging in nationwide cancer registries. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 838.e1-838.e6.	1.6	2
74	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2021, 4, 927-942.	5.4	40
75	Prognostic Factors for Contralateral Recurrence of Upper Tract Urothelial Carcinoma after Nephroureterectomy: A Large Multiregional Study. <i>Cancers</i> , 2021, 13, 5935.	3.7	5
76	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. <i>European Urology</i> , 2020, 3, 198-206.	5.4	9
77	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. <i>Oncogene</i> , 2020, 39, 6265-6285.	5.9	52
78	Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. <i>European Urology</i> , 2020, 77, 290-292.	1.9	48
79	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	1.6	29
80	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 496-505.	1.6	6
81	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	1.6	15
82	Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. <i>Practical Radiation Oncology</i> , 2020, 10, e82-e90.	2.1	19
83	Critical treatment choices for patients with platinum-refractory urothelial carcinoma. <i>Lancet Oncology</i> , 2020, 21, 11-13.	10.7	1
84	Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 77, 583-598.	1.9	40
85	Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e1-929.e10.	1.6	7
86	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2020, 39, 2567-2577.	2.2	6
87	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy? <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 736.e11-736.e18.	1.6	8
88	Initial Results from the M-STONE Group: A Multi-Center Collaboration to Study Treatment Outcomes in Nephrolithiasis Evaluation. <i>Journal of Endourology</i> , 2020, 34, 919-923.	2.1	5
89	Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. <i>BJU International</i> , 2020, 128, 57-64.	2.5	14
90	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. <i>Cancer</i> , 2020, 126, 4362-4370.	4.1	14

#	ARTICLE	IF	CITATIONS
91	<p>The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States</p>. Cancer Management and Research, 2020, Volume 12, 9825-9836.	1.9	3
92	Office-Based Blue Light Flexible Cystoscopy Improves Diagnostic Capabilities. Videourology (New) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	0
93	Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 933.e7-933.e12.	1.6	10
94	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 737.e11-737.e16.	1.6	10
95	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 639.e1-639.e9.	1.6	15
96	Novel technologies that change the diagnostic and treatment paradigm in urology. Current Opinion in Urology, 2020, 30, 477-478.	1.8	1
97	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 604.e9-604.e17.	1.6	77
98	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. Journal of Clinical Medicine, 2020, 9, 1218.	2.4	5
99	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. European Urology Oncology, 2020, 3, 420-423.	5.4	29
100	A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging. Journal of Urology, 2020, 204, 239-246.	0.4	7
101	Microhematuria: AUA/SUFU Guideline. Journal of Urology, 2020, 204, 778-786.	0.4	133
102	Implementation of a Urology E-Consult Service at a Safety Net County Hospital. Urology Practice, 2020, 7, 448-453.	0.5	4
103	Reply by Authors. Journal of Urology, 2020, 204, 246-246.	0.4	0
104	Financial Considerations in the Management of Small Renal Masses. , 2020, , 31-40.		0
105	Urinary-Based Markers for Bladder Cancer Detection. SociÃ©tÃ© Internationale D'urologie Journal, 2020, 1, 49-61.	0.4	3
106	Clinical Utility of Bladder Cancer Biomarkers. SociÃ©tÃ© Internationale D'urologie Journal, 2020, 1, 62-67.	0.4	1
107	Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU International, 2019, 123, 35-41.	2.5	16
108	Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal of Clinical Medicine, 2019, 8, 1192.	2.4	13

#	ARTICLE	IF	CITATIONS
109	Current advances in BCG-unresponsive non-muscle invasive bladder cancer. Expert Opinion on Investigational Drugs, 2019, 28, 757-770.	4.1	21
110	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 758-764.	1.6	21
111	Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer. Trends in Cancer, 2019, 5, 426-439.	7.4	52
112	DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. Carcinogenesis, 2019, 40, 1332-1340.	2.8	7
113	Evaluation of Hematuria in a Large Public Health Care System. Bladder Cancer, 2019, 5, 119-129.	0.4	20
114	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Medicine, 2019, 11, 60.	8.2	36
115	FP131COST ANALYSIS OF INCREASED WATER INTAKE ON RECURRENT CYSTITIS BASED ON RESULTS FROM A RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
116	Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. European Urology Oncology, 2019, 2, 691-698.	5.4	18
117	Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 158525.	2.4	15
118	Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. European Urology, 2019, 76, 238-243.	1.9	29
119	Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. European Urology, 2019, 76, 200-206.	1.9	41
120	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA " update 2018. Nature Reviews Urology, 2019, 16, 377-386.	3.8	51
121	Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. Clinical Cancer Research, 2019, 25, 3689-3701.	7.0	81
122	Delivery of Bottled Water to Women With Recurrent Urinary Tract Infections: Why in Bulgaria?"Reply. JAMA Internal Medicine, 2019, 179, 449.	5.1	0
123	Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 478-484.	1.6	11
124	Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy. Lancet Oncology, The, 2019, 20, 473-475.	10.7	4
125	Progress toward a Nordic standard for the investigation of hematuria: 2019. Scandinavian Journal of Urology, 2019, 53, 8-8.	1.0	0
126	Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clinical Cancer Research, 2019, 25, 3908-3920.	7.0	71

#	ARTICLE	IF	CITATIONS
127	Recent advances in the metabolomic study of bladder cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 315-324.	3.0	28
128	Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts. <i>International Journal of Molecular Sciences</i> , 2019, 20, 793.	4.1	25
129	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. <i>World Journal of Urology</i> , 2019, 37, 2419-2427.	2.2	9
130	Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. <i>European Urology Oncology</i> , 2019, 2, 397-404.	5.4	42
131	Is Cystoscopy a Major Source of Discomfort and Anxiety for Bladder Cancer Patients?. <i>Journal of the American College of Surgeons</i> , 2019, 229, S317.	0.5	0
132	Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. <i>European Urology</i> , 2019, 75, 853-860.	1.9	68
133	Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate. <i>American Journal of Roentgenology</i> , 2019, 212, 576-581.	2.2	13
134	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 57-62.	1.6	24
135	Validating the predictors of outcomes after radical cystectomy for bladder cancer. <i>Cancer</i> , 2019, 125, 223-231.	4.1	27
136	Effect of blue-light cystoscopy on contemporary performance of urine cytology. <i>BJU International</i> , 2019, 124, 251-257.	2.5	10
137	Molecular markers in bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 31-40.	2.2	86
138	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2019, 5, 97-103.	3.1	3
139	Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test. <i>European Urology Focus</i> , 2019, 5, 664-675.	3.1	5
140	Clinical Validation of IsoPSA, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer. <i>Journal of Urology</i> , 2019, 201, 1115-1120.	0.4	13
141	Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. <i>Journal of Urology</i> , 2019, 202, 920-926.	0.4	19
142	Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis. <i>Journal of Urology</i> , 2019, 202, 1136-1142.	0.4	20
143	Challenging cases in urology: Hematuria in a man with prune belly syndrome. <i>Urology Times</i> , 2019, 8, 9-10.	0.0	0
144	Diagnostic Utility of a Likert Scale Versus Qualitative Descriptors and Length of Capsular Contact for Determining Extraprostatic Tumor Extension at Multiparametric Prostate MRI. <i>American Journal of Roentgenology</i> , 2018, 210, 1066-1072.	2.2	42

#	ARTICLE	IF	CITATIONS
145	Re: Who Should be Investigated for Hematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. <i>European Urology</i> , 2018, 74, 15-16.	1.9	2
146	Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 434-440.	2.5	13
147	Current approaches for identifying high-risk non-muscle invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 223-235.	2.4	6
148	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. <i>Journal of Urology</i> , 2018, 199, 1158-1165.	0.4	82
149	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. <i>Urology</i> , 2018, 112, 103-111.	1.0	15
150	Reply by Authors. <i>Urology Practice</i> , 2018, 5, 131-131.	0.5	0
151	Advancements in optical techniques and imaging in the diagnosis and management of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 97-102.	1.6	9
152	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 159.e7-159.e17.	1.6	21
153	Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood. <i>Molecular Pathology Library</i> , 2018, , 117-136.	0.1	0
154	Cost-effectiveness of antimicrobial prophylaxis for children in the RIVUR trial. <i>World Journal of Urology</i> , 2018, 36, 1441-1447.	2.2	9
155	Prospective Monitoring and Adapting Strategies for Prevention of Infection Following Transrectal Prostate Procedures. <i>Urology Practice</i> , 2018, 5, 124-131.	0.5	0
156	Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. <i>European Urology Focus</i> , 2018, 4, 907-915.	3.1	40
157	Impact of hospital case volume on testicular cancer outcomes and practice patterns. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e7-14.e15.	1.6	55
158	Development of a 90-Minute Integrated Noninvasive Urinary Assay for Bladder Cancer Detection. <i>Journal of Urology</i> , 2018, 199, 655-662.	0.4	48
159	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 88.e11-88.e18.	1.6	15
160	Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 89.e1-89.e5.	1.6	6
161	Natural history of second™ biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study. <i>BJU International</i> , 2018, 121, 365-372.	2.5	12
162	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. <i>European Urology</i> , 2018, 74, 784-795.	1.9	530

#	ARTICLE	IF	CITATIONS
163	Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections. <i>JAMA Internal Medicine</i> , 2018, 178, 1509.	5.1	187
164	A Festschrift in Honor of Edward M. Messing, MD, FACS. <i>Bladder Cancer</i> , 2018, 4, S1-S43.	0.4	0
165	Seniority of primary care physicians is associated with a decrease in PSA ordering habits in the years surrounding the United States Preventative Services Task Force recommendation against PSA screening. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 500.e21-500.e27.	1.6	0
166	Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer. <i>Current Opinion in Urology</i> , 2018, 28, 577-583.	1.8	14
167	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1221-e1235.	1.9	14
168	Pathological characteristics and prognostic indicators of different histopathological types of urinary bladder cancer following radical cystectomy in a large single-center Egyptian cohort. <i>World Journal of Urology</i> , 2018, 36, 1835-1843.	2.2	13
169	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. <i>European Urology Oncology</i> , 2018, 1, 242-251.	5.4	14
170	Editorial Comment. <i>Urology</i> , 2018, 118, 111-112.	1.0	2
171	The use of blue light flexible cystoscopy with hexaminolevulinate & the diagnosis of bladder cancer. <i>Future Oncology</i> , 2018, 14, 2805-2810.	2.4	3
172	An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1981-1995.	2.2	95
173	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 343.e1-343.e8.	1.6	4
174	Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. <i>Cell Metabolism</i> , 2018, 28, 793-800.e2.	16.2	193
175	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. <i>European Urology Oncology</i> , 2018, 1, 223-230.	5.4	25
176	Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2018, 36, 112-112.	1.6	2
177	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study. <i>Journal of Clinical Oncology</i> , 2018, 36, 586-586.	1.6	1
178	Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer. <i>Oncotarget</i> , 2018, 9, 7101-7111.	1.8	21
179	Grade progression in urothelial carcinoma can occur with high or low mutational homology: a first-step toward tumor-specific care in initial low-grade bladder cancer. <i>Oncotarget</i> , 2018, 9, 9415-9424.	1.8	4
180	A genomic classifier for identifying a neuroendocrine-like bladder cancer subtype. <i>Journal of Clinical Oncology</i> , 2018, 36, 440-440.	1.6	2

#	ARTICLE	IF	CITATIONS
181	Editorial response to "Clinical complete response to neoadjuvant chemotherapy for muscle-invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study" Translational Cancer Research, 2018, 7, S752-S754.	1.0	0
182	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	2.2	33
183	Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer. World Journal of Urology, 2017, 35, 105-111.	2.2	6
184	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. BJU International, 2017, 119, 234-238.	2.5	16
185	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 113-120.	2.2	22
186	The kidney stone and increased water intake trial in steel workers: results from a pilot study. Urolithiasis, 2017, 45, 177-183.	2.0	18
187	Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 612-620.	1.3	10
188	Decision Analysis Model Comparing Cost of Management Strategies for Pelvic Fracture Urethral Injuries. Urology Practice, 2017, 4, 285-289.	0.5	2
189	Guideline of guidelines: non-muscle-invasive bladder cancer. BJU International, 2017, 119, 371-380.	2.5	195
190	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
191	Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma. BJU International, 2017, 119, 741-747.	2.5	15
192	The economics of stone disease. World Journal of Urology, 2017, 35, 1321-1329.	2.2	32
193	Epidemiology of stone disease across the world. World Journal of Urology, 2017, 35, 1301-1320.	2.2	520
194	Bladder cancer. Nature Reviews Disease Primers, 2017, 3, 17022.	30.5	590
195	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROIMPACT study. Cancer, 2017, 123, 2850-2859.	4.1	66
196	Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. Journal of Urology, 2017, 198, 1021-1026.	0.4	2
197	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. Journal of Urology, 2017, 198, 552-559.	0.4	632
198	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	7.1	120

#	ARTICLE	IF	CITATIONS
199	Lynch syndrome in upper tract urothelial carcinoma. <i>Current Opinion in Urology</i> , 2017, 27, 48-55.	1.8	29
200	Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 689-695.e2.	1.9	14
201	Tackling non-muscle invasive bladder cancer in the clinic. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 467-480.	2.4	11
202	Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. <i>Scientific Reports</i> , 2017, 7, 40714.	3.3	41
203	Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 531.e15-531.e22.	1.6	94
204	Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. <i>Journal of Urology</i> , 2017, 197, 1419-1426.	0.4	82
205	An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancerâ€”Preliminary experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 149.e15-149.e21.	1.6	21
206	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , 2017, 171, 540-556.e25.	28.9	1,742
207	Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 588-597.	1.5	46
208	Tissue-based biomarkers in prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 249-260.	0.7	20
209	Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 660.e17-660.e25.	1.6	5
210	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e1039-e1045.	1.9	14
211	Re: Multi-institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy. <i>European Urology</i> , 2017, 72, 857-858.	1.9	0
212	Metabolomics analysis reveals distinct profiles of nonmuscleâ€invasive and muscleâ€invasive bladder cancer. <i>Cancer Medicine</i> , 2017, 6, 2106-2120.	2.8	57
213	Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. <i>Medical Dosimetry</i> , 2017, 42, 341-347.	0.9	23
214	Editorial comment. <i>Current Opinion in Urology</i> , 2017, 27, 34.	1.8	0
215	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. <i>Journal of Urology</i> , 2017, 198, 1269-1277.	0.4	5
216	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 198, 1253-1262.	0.4	58

#	ARTICLE	IF	CITATIONS
217	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 580-589.	0.4	35
218	Superior Cost Effectiveness of Penile Plication vs Intralesional Collagenase Injection for Treatment of Peyronie's Disease Deformities. <i>Urology Practice</i> , 2017, 4, 118-125.	0.5	20
219	A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. <i>Journal of Urology</i> , 2017, 197, 1208-1213.	0.4	45
220	Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). <i>World Journal of Urology</i> , 2017, 35, 379-387.	2.2	260
221	Early and multiple PSA bounces can occur following high-dose prostate stereotactic body radiation therapy: Subset analysis of a phase 1/2 trial. <i>Practical Radiation Oncology</i> , 2017, 7, e43-e49.	2.1	15
222	Prevention of Recurrent Acute Uncomplicated Cystitis by Increasing Daily Water in Premenopausal Women: A Prospective, Randomized, Controlled Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S736-S736.	0.9	5
223	Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. <i>Oncotarget</i> , 2017, 8, 95620-95631.	1.8	38
224	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	2.0	12
225	Intravesical rAd β IFN \pm /Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3410-3416.	1.6	124
226	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 621-625.	2.5	40
227	Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer. <i>Translational Andrology and Urology</i> , 2017, 6, 345-354.	1.4	23
228	Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer. <i>Oncotarget</i> , 2017, 8, 722-741.	1.8	22
229	Review of the Clinical Approaches to the Use of Urine-based Tumor Markers in Bladder Cancer. <i>Rambam Maimonides Medical Journal</i> , 2017, 8, e0040.	1.0	11
230	Alternative therapies in patients with non-muscle invasive bladder cancer. <i>Turkish Journal of Urology</i> , 2017, 43, 414-424.	1.3	8
231	Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-24.	1.6	0
232	Value of nutrition supplementation prior to cystectomy. <i>Canadian Journal of Urology</i> , 2017, 24, 8902.	0.0	0
233	Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study. <i>Bladder Cancer</i> , 2016, 2, 91-99.	0.4	8
234	Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. <i>BJU International</i> , 2016, 117, 783-786.	2.5	68

#	ARTICLE	IF	CITATIONS
235	Long-term outcomes in a high-risk bladder cancer screening cohort. <i>BJU International</i> , 2016, 117, 611-617.	2.5	14
236	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. <i>BJU International</i> , 2016, 118, 243-249.	2.5	14
237	Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses. <i>Journal of Endourology</i> , 2016, 30, S-28-S-33.	2.1	16
238	Analysis of genetics to identify susceptibility to secondary malignancies in patients with bladder cancer. <i>BJU International</i> , 2016, 118, 12-13.	2.5	1
239	Stereotactic body radiation therapy for low and intermediate risk prostate cancer—Results from a multi-institutional clinical trial. <i>European Journal of Cancer</i> , 2016, 59, 142-151.	2.8	124
240	Decision analysis model evaluating the cost of a temporary hydrogel rectal spacer before prostate radiation therapy to reduce the incidence of rectal complications. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 291.e19-291.e26.	1.6	29
241	Re: Efficacy of High-intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score—Weighted Analysis from the National Cancer Data Base. <i>European Urology</i> , 2016, 70, 893.	1.9	0
242	Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening. <i>Cancer</i> , 2016, 122, 3785-3793.	4.1	23
243	Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma. <i>Urology</i> , 2016, 96, 44-53.	1.0	10
244	Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1189-1199.	3.1	8
245	Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 531.e1-531.e6.	1.6	26
246	Lymphovascular invasion is associated with oncologic outcomes following radical cystectomy for squamous cell carcinoma of the urinary bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 417.e1-417.e8.	1.6	14
247	Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 485.e7-485.e14.	1.6	19
248	Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2016, 196, 1627-1633.	0.4	36
249	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. <i>Urology</i> , 2016, 94, 314.e1-314.e7.	1.0	16
250	Bladder cancer. <i>Lancet</i> , The, 2016, 388, 2796-2810.	13.7	1,031
251	Comparison of prostate cancer detection at 3-T MRI with and without an endorectal coil: A prospective, paired-patient study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 255.e7-255.e13.	1.6	37
252	Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. <i>EBioMedicine</i> , 2016, 7, 85-93.	6.1	6

#	ARTICLE	IF	CITATIONS
253	The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. <i>European Urology Focus</i> , 2016, 2, 79-85.	3.1	39
254	Magnetic resonance/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of prostate cancer: multi-institutional retrospective analysis of 389 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 416.e9-416.e14.	1.6	31
255	Should patients newly diagnosed with bladder cancer be screened for lung cancer?. <i>International Journal of Urology</i> , 2016, 23, 346-347.	1.0	4
256	Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. <i>Journal of Urology</i> , 2016, 195, 1911-1919.	0.4	35
257	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 167.e9-167.e16.	1.6	26
258	Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 233.e1-233.e6.	1.6	22
259	Use of an Electronic Medical Record to Assess Patient-Reported Morbidity Following Ureteroscopy. <i>Journal of Endourology</i> , 2016, 30, S-46-S-51.	2.1	11
260	The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. <i>Journal of Urology</i> , 2016, 196, 321-326.	0.4	14
261	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. <i>World Journal of Urology</i> , 2016, 34, 1155-1161.	2.2	4
262	The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 296-302.	1.6	22
263	Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. <i>Urologic Clinics of North America</i> , 2016, 43, 47-62.	1.8	71
264	Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2016, 43, 105-118.	1.8	9
265	Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?. <i>Journal of Urology</i> , 2016, 195, 886-893.	0.4	71
266	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. <i>European Urology</i> , 2016, 69, 300-310.	1.9	460
267	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. <i>World Journal of Urology</i> , 2016, 34, 105-112.	2.2	7
268	A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy. <i>Journal of Urology</i> , 2016, 195, 53-59.	0.4	95
269	Assessment of Prospectively Assigned Likert Scores for Targeted Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsies in Patients with Suspected Prostate Cancer. <i>Journal of Urology</i> , 2016, 195, 80-87.	0.4	27
270	Reimbursement for Prostate Cancer Treatment. , 2016, , 367-374.		0

#	ARTICLE	IF	CITATIONS
271	Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5053-5053.	1.6	0
272	Effect of a genomic classifier on treatment decision-making among patients with biochemical recurrence after radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16558-e16558.	1.6	0
273	Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma. <i>Canadian Journal of Urology</i> , 2016, 23, 8334-41.	0.0	4
274	Costâ€Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension. <i>Journal of Clinical Hypertension</i> , 2015, 17, 713-719.	2.0	20
275	Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 268.e1-268.e7.	1.6	24
276	Lynch Syndrome: A Primer for Urologists and Panel Recommendations. <i>Journal of Urology</i> , 2015, 194, 21-29.	0.4	66
277	We Should Screen Smokers for Bladder and Kidney Cancer. <i>European Urology Focus</i> , 2015, 1, 50-51.	3.1	1
278	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	1.9	235
279	Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. <i>European Urology</i> , 2015, 67, 803-812.	1.9	78
280	Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 677-682.	2.5	17
281	Utility of Biomarkers in the Prediction of Oncologic Outcome after Radical Cystectomy for Squamous Cell Carcinoma. <i>Journal of Urology</i> , 2015, 193, 451-456.	0.4	15
282	Capsule Commentary on Bassett et al., Gender, Race, and Variations in the Evaluation of Microscopic Hematuria Among Medicare Beneficiaries. <i>Journal of General Internal Medicine</i> , 2015, 30, 491-491.	2.6	0
283	Promises and challenges of fluorescence cystoscopy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 261-264.	1.6	11
284	Molecular Markers for Bladder Cancer Screening, Early Diagnosis, and Surveillance: The WHO/ICUD Consensus. <i>Urologia Internationalis</i> , 2015, 94, 1-24.	1.3	149
285	Association of Distance to Treatment Facility on Quality and Survival Outcomes After Radical Cystectomy for Bladder Cancer. <i>Urology</i> , 2015, 85, 876-882.	1.0	27
286	Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 71.e21-71.e26.	1.6	26
287	Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 65.e19-65.e25.	1.6	43
288	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	1.6	11

#	ARTICLE	IF	CITATIONS
289	Role of fibroblast growth factor in squamous cell carcinoma of the bladder: Prognostic biomarker and potential therapeutic target. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 111.e1-111.e7.	1.6	8
290	Decision analysis model comparing cost of multiparametric magnetic resonance imaging vs. repeat biopsy for detection of prostate cancer in men with prior negative findings on biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 266.e9-266.e16.	1.6	32
291	Cost-Effectiveness in Minimally Invasive Urologic Surgery. , 2015, , 239-250.		1
292	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 495.e15-495.e22.	1.6	15
293	Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. <i>Urology</i> , 2015, 86, 1146-1152.	1.0	25
294	ATDC/TRIM29 Drives Invasive Bladder Cancer Formation through miRNA-Mediated and Epigenetic Mechanisms. <i>Cancer Research</i> , 2015, 75, 5155-5166.	0.9	59
295	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. <i>BMC Urology</i> , 2015, 15, 24.	1.4	11
296	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2015, 33, 1965-1972.	2.2	9
297	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2015, 193, 1486-1493.	0.4	38
298	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e21-18.e26.	1.6	8
299	Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?. <i>World Journal of Urology</i> , 2015, 33, 1309-1313.	2.2	41
300	Adjuvant cisplatinâ€based combined chemotherapy for lymph node (<sc>LN</sc>)â€positive urothelial carcinoma of the bladder (<sc>UCB</sc>) after radical cystectomy (<sc>RC</sc>): a retrospective international study of >1500 patients. <i>BJU International</i> , 2015, 115, 722-727.	2.5	22
301	The role of adjuvant chemotherapy for lymph nodeâ€positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. <i>BJU International</i> , 2015, 116, 72-78.	2.5	29
302	Spectrum of diverse genomic alterations define nonâ€clear cell renal carcinoma subtypes. <i>Nature Genetics</i> , 2015, 47, 13-21.	21.4	310
303	Histologic upgrading in patients eligible for active surveillance on saturation biopsy. <i>Canadian Journal of Urology</i> , 2015, 22, 7656-60.	0.0	6
304	Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. <i>Canadian Journal of Urology</i> , 2015, 22, 7865-75.	0.0	17
305	Bladder Cancer Biomarker Discovery Using Global Metabolomic Profiling of Urine. <i>PLoS ONE</i> , 2014, 9, e115870.	2.5	99
306	Triglycerides in the Human Kidney Cortex: Relationship with Body Size. <i>PLoS ONE</i> , 2014, 9, e101285.	2.5	58

#	ARTICLE	IF	CITATIONS
307	Re: Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. <i>European Urology</i> , 2014, 66, 968-969.	1.9	0
308	Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 699-706.	3.4	32
309	^{Ki67} is an independent predictor of oncological outcomes in patients with localized clear cell renal cell carcinoma. <i>BJU International</i> , 2014, 113, 668-673.	2.5	49
310	Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. <i>BJU International</i> , 2014, 113, 70-76.	2.5	38
311	Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4251-4256.	7.1	110
312	Prospective Comparison of Molecular Signatures in Urothelial Cancer of the Bladder and the Upper Urinary Tract—Is There Evidence for Discordant Biology?. <i>Journal of Urology</i> , 2014, 191, 926-931.	0.4	29
313	Lymphovascular invasion in clear cell renal cell carcinoma—Association with disease-free and cancer-specific survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e23-30.e28.	1.6	24
314	Squamous cell carcinogenesis and squamous cell carcinoma of the urinary bladder: A contemporary review with focus on nonbilharzial squamous cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 32.e11-32.e16.	1.6	21
315	Dysregulation of β -Catenin is an Independent Predictor of Oncologic Outcomes in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 1671-1677.	0.4	22
316	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. <i>Urology</i> , 2014, 83, 863-868.	1.0	82
317	Prospective Analysis of Ki-67 as an Independent Predictor of Oncologic Outcomes in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2014, 191, 28-34.	0.4	35
318	Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 49.e7-49.e14.	1.6	38
319	Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 625-630.	1.6	25
320	Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. <i>European Urology</i> , 2014, 66, 913-919.	1.9	103
321	Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. <i>European Urology</i> , 2014, 65, 650-658.	1.9	134
322	What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 128-134.	1.6	53
323	Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 230-242.	1.6	33
324	The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. <i>European Urology</i> , 2014, 66, 253-262.	1.9	418

#	ARTICLE	IF	CITATIONS
325	From genomics to imagingâ€”advances along the care continuum. <i>Nature Reviews Urology</i> , 2014, 11, 71-73.	3.8	0
326	Urine markers for detection and surveillance of bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 222-229.	1.6	91
327	Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. <i>International Archives of Occupational and Environmental Health</i> , 2014, 87, 715-724.	2.3	45
328	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2014, 66, 379-385.	1.9	27
329	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 981-988.	1.6	39
330	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. <i>Urology</i> , 2014, 84, 1134-1140.	1.0	18
331	Electrophysiological analysis of biopsy samples using elasticity as an inherent cell marker for cancer detection. <i>Analytical Methods</i> , 2014, 6, 7166-7174.	2.7	23
332	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4066-4072.	1.6	234
333	Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in 2030. <i>European Urology</i> , 2014, 66, 724-729.	1.9	233
334	Medical management strategies to prevent recurrent nephrolithiasis are stagnant and stronger evidence is needed to reduce morbidity. <i>Evidence-Based Medicine</i> , 2014, 19, 12-12.	0.6	1
335	Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. <i>European Urology</i> , 2014, 66, 439-446.	1.9	24
336	Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2014, 191, 1238-1243.	0.4	26
337	Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. <i>European Urology</i> , 2014, 66, 361-370.	1.9	125
338	Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 37.e17-37.e23.	1.6	21
339	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 54.e19-54.e26.	1.6	31
340	Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 47.e1-47.e8.	1.6	8
341	Prospective External Validation of a Bladder Cancer Detection Model. <i>Journal of Urology</i> , 2014, 192, 1343-1348.	0.4	35
342	Predictors of Rectal Tolerance Observed in a Dose-Escalated Phase 1-2 Trial of Stereotactic Body Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 509-517.	0.8	177

#	ARTICLE	IF	CITATIONS
343	BAP1 Immunohistochemistry Predicts Outcomes in a Multi-Institutional Cohort with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 191, 603-610.	0.4	69
344	Costs of Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2014, 65, 316-324.	1.9	84
345	Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15518-e15518.	1.6	2
346	Abstract B24: ATDC (Trim29) drives invasive bladder cancer formation. , 2014, , .		0
347	Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. <i>BJU International</i> , 2013, 111, 74-84.	2.5	26
348	Systematic Review of Complications of Prostate Biopsy. <i>European Urology</i> , 2013, 64, 876-892.	1.9	779
349	Metabolomic signatures of aggressive prostate cancer. <i>Prostate</i> , 2013, 73, 1547-1560.	2.3	117
350	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. <i>Cell</i> , 2013, 154, 1074-1084.	28.9	257
351	Prediction of True Nodal Status in Patients with Pathological Lymph Node Negative Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>Journal of Urology</i> , 2013, 189, 468-473.	0.4	40
352	Comprehensive handbook for developing a bladder cancer cystectomy database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 812-826.	1.6	7
353	Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1662-1667.	0.4	23
354	Cumulative Number of Altered Biomarkers in Mammalian Target of Rapamycin Pathway Is an Independent Predictor of Outcome in Patients With Clear Cell Renal Cell Carcinoma. <i>Urology</i> , 2013, 81, 581-586.	1.0	37
355	Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy. <i>European Urology</i> , 2013, 63, 371-378.	1.9	47
356	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. <i>European Urology</i> , 2013, 63, 4-15.	1.9	225
357	Epidemiology and Risk Factors of Urothelial Bladder Cancer. <i>European Urology</i> , 2013, 63, 234-241.	1.9	1,572
358	Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. <i>BJU International</i> , 2013, 111, E30-6.	2.5	77
359	Re: Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2013, 63, 580-581.	1.9	4
360	Reduction in Hospital Admission Rates Due to Post-Prostate Biopsy Infections After Augmenting Standard Antibiotic Prophylaxis. <i>Journal of Urology</i> , 2013, 189, 535-540.	0.4	84

#	ARTICLE	IF	CITATIONS
361	Cost-Effectiveness of Fluorescence In Situ Hybridization in Patients with Atypical Cytology for the Detection of Urothelial Carcinoma. <i>Journal of Urology</i> , 2013, 190, 1181-1186.	0.4	35
362	Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Cancer</i> , 2013, 49, 1889-1897.	2.8	154
363	How Much is a Kidney Worth? Cost-Effectiveness of Routine Imaging After Ureteroscopy to Prevent Silent Obstruction. <i>Journal of Urology</i> , 2013, 189, 2136-2141.	0.4	23
364	Controlling Health Care Costs for Prostate Cancer. <i>European Urology</i> , 2013, 64, 17-18.	1.9	2
365	Summary of the 6th annual bladder cancer think tank: New directions in urologic research. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 968-973.	1.6	6
366	Impact of Smoking and Smoking Cessation on Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2013, 64, 456-464.	1.9	101
367	Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. <i>European Urology</i> , 2013, 64, 837-845.	1.9	61
368	Urinary cytology for the detection of urothelial carcinoma of the bladder—a flawed adjunct to cystoscopy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 366-371.	1.6	14
369	Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. <i>BJU International</i> , 2013, 111, 1054-1060.	2.5	38
370	Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives. <i>European Urology</i> , 2013, 63, 1049-1058.	1.9	64
371	Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy. <i>European Urology</i> , 2013, 64, 465-471.	1.9	68
372	Effect of statin use on outcomes of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2013, 112, E4-12.	2.5	26
373	Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. <i>Annals of Surgical Oncology</i> , 2013, 20, 1027-1034.	1.5	25
374	Impact of fluid intake in the prevention of urinary system diseases. <i>Current Opinion in Nephrology and Hypertension</i> , 2013, 22, S1-S10.	2.0	58
375	Pathogenesis and Cost-Effectiveness of Preventing Kidney Stones. <i>Nutrition Today</i> , 2013, 48, S22-S24.	1.0	0
376	Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?. <i>BJU International</i> , 2013, 112, 1053-1254.	2.5	2
377	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephroureterectomy. <i>BJU International</i> , 2013, 112, 453-461.	2.5	128
378	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. <i>BJU International</i> , 2013, 111, 1215-1221.	2.5	55

#	ARTICLE	IF	CITATIONS
379	Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e31s-e37s.	2.5	78
380	Is robotic surgery cost-effective. <i>Current Opinion in Urology</i> , 2012, 22, 66-69.	1.8	47
381	A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma. <i>Science Translational Medicine</i> , 2012, 4, 137ra75.	12.4	159
382	Cost Comparison of Robot-Assisted and Laparoscopic Pyeloplasty. <i>Journal of Endourology</i> , 2012, 26, 1044-1048.	2.1	24
383	Three differentiation states risk-stratify bladder cancer into distinct subtypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2078-2083.	7.1	232
384	BAP1 loss defines a new class of renal cell carcinoma. <i>Nature Genetics</i> , 2012, 44, 751-759.	21.4	791
385	Stage-Specific Impact of Tumor Location on Oncologic Outcomes in Patients With Upper and Lower Tract Urothelial Carcinoma Following Radical Surgery. <i>European Urology</i> , 2012, 62, 677-684.	1.9	93
386	Editorial Comment. <i>Journal of Urology</i> , 2012, 187, 127-128.	0.4	0
387	Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. <i>Journal of Urology</i> , 2012, 187, 457-462.	0.4	43
388	Evaluation of Vitamin E and Selenium Supplementation for the Prevention of Bladder Cancer in SWOG Coordinated SELECT. <i>Journal of Urology</i> , 2012, 187, 2005-2010.	0.4	41
389	Cost-Effectiveness of Fluorescent Cystoscopy for Noninvasive Papillary Tumors. <i>Journal of Urology</i> , 2012, 187, 1537-1539.	0.4	2
390	Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. <i>Annals of Surgical Oncology</i> , 2012, 19, 4337-4344.	1.5	53
391	Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 273-277.	1.6	29
392	The impact of biomarkers in multivariate algorithms for bladder cancer diagnosis in patients with hematuria. <i>Cancer</i> , 2012, 118, 2566-2567.	4.1	0
393	Biomolecular Predictors of Urothelial Cancer Behavior and Treatment Outcomes. <i>Current Urology Reports</i> , 2012, 13, 122-135.	2.2	51
394	The Challenges of Harnessing New Technology. <i>European Urology</i> , 2012, 61, 269-270.	1.9	1
395	Death Certificates Are Valid for the Determination of Cause of Death in Patients With Upper and Lower Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 61, 854-855.	1.9	152
396	Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. <i>European Urology</i> , 2012, 62, e27-e29.	1.9	17

#	ARTICLE	IF	CITATIONS
397	Re: Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients with Early-stage Kidney Cancer. <i>European Urology</i> , 2012, 62, 352-353.	1.9	1
398	Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. <i>BJU International</i> , 2012, 109, 685-690.	2.5	30
399	Cost-effectiveness of standard vs intensive antibiotic regimens for transrectal ultrasonography (TRUS)-guided prostate biopsy prophylaxis. <i>BJU International</i> , 2012, 110, E86-91.	2.5	42
400	Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. <i>BJU International</i> , 2012, 110, 961-966.	2.5	12
401	Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey. <i>BJU International</i> , 2012, 110, 967-972.	2.5	27
402	Primary prevention of nephrolithiasis is cost-effective for a national healthcare system. <i>BJU International</i> , 2012, 110, E1060-7.	2.5	58
403	ATDC as a novel oncogene in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 269-269.	1.6	0
404	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 281-281.	1.6	0
405	Novel oncogenic function of ATDC in bladder cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4591-4591.	1.6	0
406	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4678-TPS4678.	1.6	0
407	Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: con. <i>Journal of Urology</i> , 2012, 187, 1538-9.	0.4	3
408	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. <i>BJU International</i> , 2011, 108, 687-692.	2.5	28
409	Prognostic Value of Cyclooxygenase-2 Expression in Squamous Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2011, 185, 1112-1117.	0.4	7
410	Prognostic Risk Stratification of Pathological Stage T3N0 Bladder Cancer After Radical Cystectomy. <i>Journal of Urology</i> , 2011, 185, 1216-1221.	0.4	32
411	Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2011, 185, 456-461.	0.4	86
412	Cost Comparison of Robotic, Laparoscopic, and Open Partial Nephrectomy. <i>Journal of Endourology</i> , 2011, 25, 447-453.	2.1	111
413	Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. <i>Cancer Research</i> , 2011, 71, 7376-7386.	0.9	166
414	Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder†. <i>Human Pathology</i> , 2011, 42, 347-355.	2.0	22

#	ARTICLE	IF	CITATIONS
415	Predictors of costs for robotic-assisted laparoscopic radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 325-329.	1.6	15
416	Practice Variation in the Surgical Management of Urinary Lithiasis. <i>Journal of Urology</i> , 2011, 186, 146-150.	0.4	67
417	Cost-Effectiveness of Primary Prevention Strategies for Nephrolithiasis. <i>Journal of Urology</i> , 2011, 186, 550-555.	0.4	34
418	Patients with a negative cystoscopy and negative Nmp22 [®] Bladderchek [®] test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2011, 37, 706-711.	1.5	3
419	Predictors of Outcome of Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer. <i>Scientific World Journal</i> , The, 2011, 11, 369-381.	2.1	72
420	Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. <i>BJU International</i> , 2011, 108, 31-37.	2.5	25
421	Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2011, 108, 1286-1291.	2.5	71
422	Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non-Muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 59, 1026-1031.	1.9	51
423	Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2011, 117, 276-282.	4.1	129
424	Mesh kits for anterior vaginal prolapse are not cost effective. <i>International Urogynecology Journal</i> , 2011, 22, 447-452.	1.4	12
425	Longitudinal evaluation of the SF-36 quality of life questionnaire in patients with kidney stones. <i>Urological Research</i> , 2011, 39, 141-146.	1.5	46
426	Detection of Bladder Cancer Using Novel DNA Methylation Biomarkers in Urine Sediments. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1483-1491.	2.5	133
427	Primary Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Pathology</i> , 2011, 135, 822-830.	0.7	21
428	Cost Utility of Prostate Cancer Chemoprevention with Dutasteride in Men with an Elevated Prostate Specific Antigen. <i>Cancer Prevention Research</i> , 2011, 4, 277-283.	1.5	11
429	Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2011, 9, 1255-1265.	3.4	97
430	Cost-effectiveness of robotic-assisted laparoscopic procedures in urologic surgery in the USA. <i>Expert Review of Medical Devices</i> , 2011, 8, 97-103.	2.8	19
431	Economics of Bladder Cancer Diagnosis and Surveillance. , 2011, , 121-137.		1
432	AUAP-3 Urothelial carcinoma at the uretero-enteric junction : multi-center evaluation of oncologic outcomes after radical nephroureterectomy. <i>Japanese Journal of Urology</i> , 2011, 102, 94.	0.1	0

#	ARTICLE	IF	CITATIONS
433	Economics of robotics in urology. <i>Current Opinion in Urology</i> , 2010, 20, 92-97.	1.8	38
434	The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons. <i>BJU International</i> , 2010, 105, 1531-1535.	2.5	40
435	Impact of Tumor Location on Prognosis for Patients with Upper Tract Urothelial Carcinoma Managed by Radical Nephroureterectomy. <i>European Urology</i> , 2010, 57, 1072-1079.	1.9	155
436	Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. <i>European Urology</i> , 2010, 57, 300-309.	1.9	159
437	Cost Comparison of Robotic, Laparoscopic, and Open Radical Prostatectomy for Prostate Cancer. <i>European Urology</i> , 2010, 57, 453-458.	1.9	239
438	Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome. <i>European Urology</i> , 2010, 58, 112-117.	1.9	51
439	Re: Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy And Tolerance. <i>European Urology</i> , 2010, 57, 1116-1117.	1.9	0
440	High-risk patients with hematuria are not evaluated according to guideline recommendations. <i>Cancer</i> , 2010, 116, 2954-2959.	4.1	66
441	p53 expression in patients with advanced urothelial cancer of the urinary bladder. <i>BJU International</i> , 2010, 105, 489-495.	2.5	69
442	Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. <i>BJU International</i> , 2010, 106, 1216-1222.	2.5	77
443	International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. <i>BJU International</i> , 2010, 105, 1402-1412.	2.5	132
444	The influence of body mass index on the cost of radical prostatectomy for prostate cancer. <i>BJU International</i> , 2010, 106, 1188-1193.	2.5	12
445	Translational research in bladder cancer: From molecular pathogenesis to useful tissue biomarkers. <i>Cancer Biology and Therapy</i> , 2010, 10, 407-415.	3.4	22
446	Characteristics and Outcomes of Patients With pT4 Urothelial Carcinoma at Radical Cystectomy: A Retrospective International Study of 583 Patients. <i>Journal of Urology</i> , 2010, 183, 87-93.	0.4	58
447	1021 PROSPECTIVE VALIDATION OF MULTIPLE BIOMARKERS FOR IMPROVED CLINICAL DECISION-MAKING IN PATIENTS WITH UROTHELIAL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2010, 183, .	0.4	3
448	Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer. <i>Journal of Urology</i> , 2010, 183, 68-75.	0.4	146
449	Residual Fragments After Percutaneous Nephrolithotomy: Cost Comparison of Immediate Second Look Flexible Nephroscopy Versus Expectant Management. <i>Journal of Urology</i> , 2010, 183, 188-193.	0.4	60
450	Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2010, 183, 62-67.	0.4	98

#	ARTICLE	IF	CITATIONS
451	Stage pT0 at Radical Cystectomy Confers Improved Survival: An International Study of 4,430 Patients. <i>Journal of Urology</i> , 2010, 184, 888-894.	0.4	64
452	Preoperative Hydronephrosis, Ureteroscopic Biopsy Grade and Urinary Cytology Can Improve Prediction of Advanced Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2010, 184, 69-73.	0.4	221
453	Soft Tissue Surgical Margin Status is a Powerful Predictor of Outcomes After Radical Cystectomy: A Multicenter Study of More Than 4,400 Patients. <i>Journal of Urology</i> , 2010, 183, 2165-2170.	0.4	186
454	Preoperative Multivariable Prognostic Model for Prediction of Nonorgan Confined Urothelial Carcinoma of the Upper Urinary Tract. <i>Journal of Urology</i> , 2010, 184, 453-458.	0.4	182
455	Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 500-503.	1.6	76
456	Role of biomarkers to predict outcomes and response to therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 97-101.	1.6	7
457	Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 441-448.	1.6	94
458	Statistical consideration for clinical biomarker research in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 389-400.	1.6	119
459	Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival. <i>BJU International</i> , 2010, 106, 1324-1329.	2.5	29
460	Characteristics and Outcomes of Patients With Clinical Carcinoma In Situ Only Treated With Radical Cystectomy: An International Study of 243 Patients. <i>Journal of Urology</i> , 2010, 183, 1757-1763.	0.4	69
461	Urothelial Bladder Cancer: Screening with Urine-Based Tumor Markers. , 2010, , 196-209.		0
462	Multi-Institutional Validation of the Predictive Value of Ki-67 Labeling Index in Patients With Urinary Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2009, 101, 114-119.	6.3	144
463	Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study. <i>Clinical Cancer Research</i> , 2009, 15, 7012-7019.	7.0	69
464	Lymphovascular Invasion Predicts Clinical Outcomes in Patients With Node-Negative Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 612-618.	1.6	260
465	Prostate cancer biomarker discovery using high performance mass spectral serum profiling. <i>Computer Methods and Programs in Biomedicine</i> , 2009, 96, 33-41.	4.7	17
466	Re: Evaluating the Learning Curve for Robot-Assisted Laparoscopic Radical Cystectomy. <i>European Urology</i> , 2009, 55, 1237-1239.	1.9	1
467	Editorial Comment on: Serum Proteomic Profiling in Patients with Bladder Cancer. <i>European Urology</i> , 2009, 56, 996-997.	1.9	1
468	Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. <i>European Urology</i> , 2009, 56, 430-442.	1.9	584

#	ARTICLE	IF	CITATIONS
469	Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. <i>Cancer</i> , 2009, 115, 1224-1233.	4.1	943
470	Key concerns about the current state of bladder cancer. <i>Cancer</i> , 2009, 115, 4096-4103.	4.1	69
471	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. <i>BJU International</i> , 2009, 103, 307-311.	2.5	160
472	Impact of body mass index on clinical and cost outcomes after radical cystectomy. <i>BJU International</i> , 2009, 104, 326-330.	2.5	19
473	Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. <i>BJU International</i> , 2009, 103, 1368-1374.	2.5	61
474	Radiofrequency ablation of small renal cortical tumours in healthy adults: renal function preservation and intermediate oncological outcome. <i>BJU International</i> , 2009, 104, 786-789.	2.5	38
475	General Anesthesia and Contrast-Enhanced Computed Tomography to Optimize Renal Percutaneous Radiofrequency Ablation: Multi-Institutional Intermediate-Term Results. <i>Journal of Endourology</i> , 2009, 23, 1099-1105.	2.1	62
476	Synchronous Bilateral Percutaneous Nephrostolithotomy: Analysis of Clinical Outcomes, Cost and Surgeon Reimbursement. <i>Journal of Urology</i> , 2009, 181, 149-153.	0.4	36
477	Predictors of Cost and Clinical Outcomes of Percutaneous Nephrostolithotomy. <i>Journal of Urology</i> , 2009, 182, 586-590.	0.4	42
478	Predictive Value of Combined Immunohistochemical Markers in Patients With pT1 Urothelial Carcinoma at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 78-84.	0.4	93
479	Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker. <i>Journal of Urology</i> , 2009, 182, 52-58.	0.4	76
480	p53 Predictive Value for pT1-2 N0 Disease at Radical Cystectomy. <i>Journal of Urology</i> , 2009, 182, 907-913.	0.4	54
481	Residual Pathological Stage at Radical Cystectomy Significantly Impacts Outcomes for Initial T2N0 Bladder Cancer. <i>Journal of Urology</i> , 2009, 182, 459-465.	0.4	15
482	How Physician and Patient Perceptions Differ Regarding Medical Management of Stone Disease. <i>Journal of Urology</i> , 2009, 182, 998-1004.	0.4	34
483	Economics and Cost of Care of Stone Disease. <i>Advances in Chronic Kidney Disease</i> , 2009, 16, 5-10.	1.4	121
484	Survivin: a promising biomarker for detection and prognosis of bladder cancer. <i>World Journal of Urology</i> , 2008, 26, 59-65.	2.2	92
485	Screening for bladder cancer: a perspective. <i>World Journal of Urology</i> , 2008, 26, 13-18.	2.2	49
486	Is there a rationale for bladder cancer screening?. <i>Current Urology Reports</i> , 2008, 9, 339-341.	2.2	6

#	ARTICLE	IF	CITATIONS
487	Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. <i>Cancer</i> , 2008, 112, 315-325.	4.1	185
488	Cost-effectiveness of prostate cancer chemoprevention. <i>Cancer</i> , 2008, 112, 1058-1065.	4.1	61
489	The Screening for Occult Renal Disease (SCORED) value is associated with a higher risk for having or developing chronic kidney disease in patients treated for small, unilateral renal masses. <i>Cancer</i> , 2008, 113, 2681-2686.	4.1	21
490	Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. <i>BJU International</i> , 2008, 101, 1362-1367.	2.5	34
491	Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. <i>BJU International</i> , 2008, 101, 1356-1361.	2.5	19
492	Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. <i>BJU International</i> , 2008, 102, 172-176.	2.5	75
493	Predicting survival after radical cystectomy for bladder cancer. <i>BJU International</i> , 2008, 102, 15-22.	2.5	48
494	Urothelial bladder cancer: biomarkers for detection and screening. <i>BJU International</i> , 2008, 102, 1234-1241.	2.5	20
495	Editorial Comment on: Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder. <i>European Urology</i> , 2008, 53, 579-580.	1.9	1
496	Cost-Effectiveness of Medical Expulsive Therapy Using Alpha-Blockers for the Treatment of Distal Ureteral Stones. <i>European Urology</i> , 2008, 53, 411-419.	1.9	103
497	Nomograms for Bladder Cancer. <i>European Urology</i> , 2008, 54, 41-53.	1.9	87
498	Reply to Peter L. Steinberg's Letter to the Editor re: Karim Bensalah, Margaret Pearle and Yair Lotan. Cost-Effectiveness of Medical Expulsive Therapy Using Alpha-Blockers for the Treatment of Distal Ureteral Stones. <i>Eur Urol</i> 2008;53:411-419. <i>European Urology</i> , 2008, 54, 469.	1.9	0
499	COMBINATION OF CELL CYCLE REGULATING BIO-MARKERS IMPROVES PROGNOSIS IN PATIENTS WITH ORGAN CONFINED UROTHELIAL CANCER AT RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2008, 179, 578-578.	0.4	7
500	Outcomes of Patients with Clinical T1 Grade 3 Urothelial Cell Bladder Carcinoma Treated with Radical Cystectomy. <i>Urology</i> , 2008, 71, 302-307.	1.0	62
501	Are Urologists Fairly Reimbursed for Complex Procedures: Failure of 22 Modifier?. <i>Urology</i> , 2008, 72, 494-497.	1.0	16
502	Impact of Body Mass Index on Cost and Clinical Outcomes After Percutaneous Nephrostolithotomy. <i>Urology</i> , 2008, 72, 756-760.	1.0	64
503	Determinants of Quality of Life for Patients With Kidney Stones. <i>Journal of Urology</i> , 2008, 179, 2238-2243.	0.4	106
504	Does Obesity Impact the Costs of Partial and Radical Nephrectomy?. <i>Journal of Urology</i> , 2008, 179, 1714-1718.	0.4	14

#	ARTICLE	IF	CITATIONS
505	Prospective Evaluation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2008, 179, 2164-2169.	0.4	75
506	Climate-related increase in the prevalence of urolithiasis in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9841-9846.	7.1	289
507	Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1401-1411.	6.3	68
508	Sirolimus in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3457-3460.	1.6	13
509	Prevention of bladder cancer recurrence by retinoic acid-ketoconazole: A promising strategy?. <i>Cancer Biology and Therapy</i> , 2008, 7, 101-102.	3.4	5
510	Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. <i>Nature Reviews Urology</i> , 2008, 5, 676-685.	1.4	33
511	Critical evaluation of urinary markers for bladder cancer detection and monitoring. <i>Reviews in Urology</i> , 2008, 10, 120-35.	0.9	64
512	Radiofrequency ablation for T1a tumors in a solitary kidney: promising intermediate oncologic and renal function outcomes. <i>Canadian Journal of Urology</i> , 2008, 15, 3980-5.	0.0	20
513	Cost-effectiveness of bladder cancer screening. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 627-632.	1.4	2
514	Bladder Cancer Screening and Future Directions in Urine-Based Markers for Bladder Urothelial Carcinoma. <i>Laboratory Medicine</i> , 2007, 38, 116-120.	1.2	0
515	Laparoscopic and Open Partial Nephrectomy: Cost Comparison with Analysis of Individual Parameters. <i>Journal of Endourology</i> , 2007, 21, 1449-1454.	2.1	14
516	Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: What Percentage of Patients Qualifies for Bladder Preservation Protocols?. <i>Current Urology</i> , 2007, 1, 24-27.	0.6	0
517	Contemporary Laparoscopic and Open Radical Retropubic Prostatectomy: Pathologic Outcomes and Kattan Postoperative Nomograms Are Equivalent. <i>Urology</i> , 2007, 69, 118-122.	1.0	8
518	In Vitro Assessment of the Efficacy of Thermal Therapy in Human Renal Cell Carcinoma. <i>Urology</i> , 2007, 70, 380-384.	1.0	22
519	Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 291-297.	1.6	30
520	Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007, 25, 468-475.	1.6	43
521	Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. <i>Human Pathology</i> , 2007, 38, 1703-1713.	2.0	76
522	Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. <i>Lancet Oncology</i> , The, 2007, 8, 128-136.	10.7	198

#	ARTICLE	IF	CITATIONS
523	Efficacy of Laser-Activated Gold Nanoshells in Ablating Prostate Cancer Cells in Vitro. <i>Journal of Endourology</i> , 2007, 21, 939-943.	2.1	104
524	Urology and the Law: Lessons From Litigation Notley R.G., Reynard J.M. and Badenoch J.: Urology and the Law: Lessons From Litigation. New York: Informa Healthcare 2007. 256 pages.. <i>Journal of Urology</i> , 2007, 178, 1126-1126.	0.4	0
525	Predictive Value of Cell Cycle Biomarkers in Nonmuscle Invasive Bladder Transitional Cell Carcinoma. <i>Journal of Urology</i> , 2007, 177, 481-487.	0.4	130
526	Expression of Cyclooxygenase-2 in Normal Urothelium, and Superficial and Advanced Transitional Cell Carcinoma of Bladder. <i>Journal of Urology</i> , 2007, 177, 1163-1168.	0.4	44
527	Economics of Stone Management. <i>Urologic Clinics of North America</i> , 2007, 34, 443-453.	1.8	63
528	Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. <i>Cancer</i> , 2007, 109, 1106-1113.	4.1	140
529	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. <i>Modern Pathology</i> , 2007, 20, 445-459.	5.5	128
530	Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. <i>BJU International</i> , 2007, 100, 287-290.	2.5	128
531	A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. <i>BJU International</i> , 2007, 100, 1015-1020.	2.5	58
532	Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. <i>BJU International</i> , 2007, 101, 070915222359003-???	2.5	22
533	Evaluation of costs and morbidity associated with laparoscopic radiofrequency ablation and laparoscopic partial nephrectomy for treating small renal tumours. <i>BJU International</i> , 2007, 101, 071008065132001-???	2.5	29
534	Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical Cystectomy. <i>European Urology</i> , 2007, 51, 137-151.	1.9	307
535	Re: Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States. <i>European Urology</i> , 2007, 51, 567-568.	1.9	0
536	Advanced Age Is Associated with Poorer Bladder Cancer-Specific Survival in Patients Treated with Radical Cystectomy. <i>European Urology</i> , 2007, 51, 699-708.	1.9	154
537	Despite PSA screening and the control by radical prostatectomy, patients treatment fails and have a PSA recurrence. <i>European Urology</i> , 2007, 52, 453-4.	1.9	1
538	Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium. <i>Journal of Urology</i> , 2006, 176, 2414-2422.	0.4	613
539	Nomogram for Predicting Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 176, 1354-1362.	0.4	185
540	Cancer Specific Outcomes in Patients With PTO Disease Following Radical Cystectomy. <i>Journal of Urology</i> , 2006, 175, 1645-1649.	0.4	48

#	ARTICLE	IF	CITATIONS
541	Efficacy of High Dose Per Fraction Radiation for Implanted Human Prostate Cancer in a Nude Mouse Model. <i>Journal of Urology</i> , 2006, 175, 1932-1936.	0.4	27
542	Clinical Outcomes Following Radical Cystectomy for Primary Nontransitional Cell Carcinoma of the Bladder Compared to Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2006, 175, 2048-2053.	0.4	157
543	Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. <i>Human Pathology</i> , 2006, 37, 1568-1576.	2.0	88
544	Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. <i>Urology</i> , 2006, 68, 538-542.	1.0	29
545	Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 338-343.	1.6	44
546	Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 561-562.	1.6	3
547	Novel blood biomarkers of human urinary bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 562-563.	1.6	1
548	A survivin gene signature predicts aggressive tumor behavior. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 563-564.	1.6	0
549	Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer. <i>Laboratory Medicine</i> , 2006, 37, 429-435.	1.2	0
550	Against the motion. <i>European Urology</i> , 2006, 49, 398-399.	1.9	1
551	For the motion. <i>European Urology</i> , 2006, 49, 396-398.	1.9	5
552	Efficacy of Ablative High-Dose-per-Fraction Radiation for Implanted Human Renal Cell Cancer in a Nude Mouse Model. <i>European Urology</i> , 2006, 50, 795-800.	1.9	65
553	Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage. <i>European Urology</i> , 2006, 50, 1254-1262.	1.9	147
554	Soluble Fas α A promising novel urinary marker for the detection of recurrent superficial bladder cancer. <i>Cancer</i> , 2006, 106, 1701-1707.	4.1	54
555	Should we screen for bladder cancer in a high-risk population?. <i>Cancer</i> , 2006, 107, 982-990.	4.1	122
556	Nomograms Provide Improved Accuracy for Predicting Survival after Radical Cystectomy. <i>Clinical Cancer Research</i> , 2006, 12, 6663-6676.	7.0	219
557	Ki-67 Is an Independent Predictor of Bladder Cancer Outcome in Patients Treated with Radical Cystectomy for Organ-Confined Disease. <i>Clinical Cancer Research</i> , 2006, 12, 7369-7373.	7.0	144
558	Radiofrequency Ablation of Renal Tumors: Intermediate-Term Results. <i>Journal of Endourology</i> , 2006, 20, 569-573.	2.1	133

#	ARTICLE	IF	CITATIONS
559	The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1485-1489.	2.5	30
560	The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. <i>BJU International</i> , 2005, 95, 977-981.	2.5	43
561	A cost comparison of nephron-sparing surgical techniques for renal tumour. <i>BJU International</i> , 2005, 95, 1039-1042.	2.5	60
562	International comparison of cost effectiveness of medical management strategies for nephrolithiasis. <i>Urological Research</i> , 2005, 33, 223-230.	1.5	73
563	Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes. <i>Journal of Clinical Oncology</i> , 2005, 23, 1911-1920.	1.6	33
564	Lymphovascular Invasion Is Independently Associated With Overall Survival, Cause-Specific Survival, and Local and Distant Recurrence in Patients With Negative Lymph Nodes at Radical Cystectomy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6533-6539.	1.6	283
565	NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER. <i>Journal of Urology</i> , 2005, 173, 1518-1525.	0.4	155
566	Economics of Stone Management. <i>EAU Update Series</i> , 2005, 3, 51-60.	0.5	3
567	Conservative management of priapism in acute spinal cord injury. <i>Urology</i> , 2005, 65, 1195-1197.	1.0	21
568	Correlation of office-based cystoscopy and cytology with histologic diagnosis: How good is the reference standard?. <i>Urology</i> , 2005, 66, 65-68.	1.0	30
569	Cost comparison of laparoscopic versus radical retropubic prostatectomy. <i>Urology</i> , 2005, 66, 557-560.	1.0	41
570	Changing Management of Organ-Confined Renal Masses. <i>Journal of Endourology</i> , 2004, 18, 263-268.	2.1	18
571	THE PERCENT OF BIOPSY CORES POSITIVE FOR CANCER IS A PREDICTOR OF ADVANCED PATHOLOGICAL STAGE AND POOR CLINICAL OUTCOMES IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2004, 171, 2209-2214.	0.4	44
572	COST-EFFECTIVENESS OF MEDICAL MANAGEMENT STRATEGIES FOR NEPHROLITHIASIS. <i>Journal of Urology</i> , 2004, 172, 2275-2281.	0.4	87
573	THE VALUE OF YOUR TIME: EVALUATION OF EFFECTS OF CHANGES IN MEDICARE REIMBURSEMENT RATES ON THE PRACTICE OF UROLOGY. <i>Journal of Urology</i> , 2004, 172, 1958-1962.	0.4	48
574	THE NEW ECONOMICS OF RADICAL PROSTATECTOMY: COST COMPARISON OF OPEN, LAPAROSCOPIC AND ROBOT ASSISTED TECHNIQUES. <i>Journal of Urology</i> , 2004, 172, 1431-1435.	0.4	263
575	Laparoscopic partial nephrectomy using holmium laser in a porcine model. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2004, 8, 51-5.	1.1	28
576	Cost-Effective Treatment for Ureteropelvic Junction Obstruction: A Decision Tree Analysis. <i>Journal of Urology</i> , 2003, 169, 228-232.	0.4	29

#	ARTICLE	IF	CITATIONS
577	Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. <i>Urology</i> , 2003, 61, 109-118.	1.0	432
578	Histopathology of surgically managed renal tumors: analysis of a contemporary series. <i>Urology</i> , 2003, 62, 827-830.	1.0	157
579	Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. <i>Urology</i> , 2003, 62, 918-921.	1.0	102
580	Cost Comparison of Hand Assisted Laparoscopic Nephrectomy and Open Nephrectomy: Analysis of Individual Parameters. <i>Journal of Urology</i> , 2003, 170, 752-755.	0.4	23
581	Laparoscopic nephrectomy is cost effective compared with open nephrectomy in a large county hospital. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2003, 7, 111-5.	1.1	8
582	Laparoscopic treatment of ovarian vein syndrome. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2003, 7, 257-60.	1.1	8
583	Clinical Use of the Holmium:YAG Laser in Laparoscopic Partial Nephrectomy. <i>Journal of Endourology</i> , 2002, 16, 289-292.	2.1	67
584	Radiofrequency Coagulation of Renal Parenchyma: Comparison of Effects of Energy Generators on Treatment Efficacy. <i>Journal of Endourology</i> , 2002, 16, 83-88.	2.1	45
585	Laparoscopic Interstitial Laser Coagulation of Renal Tissue with and without Hilar Occlusion in the Porcine Model. <i>Journal of Endourology</i> , 2002, 16, 565-570.	2.1	19
586	Laparoscopic Partial Nephrectomy with a Diode Laser: Porcine Results. <i>Journal of Endourology</i> , 2002, 16, 749-753.	2.1	45
587	Transvaginal laparoscopic nephrectomy: development and feasibility in the porcine model. <i>Urology</i> , 2002, 59, 446-450.	1.0	247
588	Cost comparison for laparoscopic nephrectomy and open nephrectomy: analysis of individual parameters. <i>Urology</i> , 2002, 59, 821-825.	1.0	30
589	Laparoscopic Versus Open Retroperitoneal Lymph Node Dissection: a Cost Analysis. <i>Journal of Urology</i> , 2002, 168, 1945-1949.	0.4	26
590	Management Of Ureteral Calculi: A Cost Comparison And Decision Making Analysis. <i>Journal of Urology</i> , 2002, 167, 1621-1629.	0.4	176
591	COST-EFFECTIVENESS OF A MODIFIED CARE PROTOCOL SUBSTITUTING BLADDER TUMOR MARKERS FOR CYSTOSCOPY FOR THE FOLLOWUP OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A DECISION ANALYTICAL APPROACH. <i>Journal of Urology</i> , 2002, 167, 75-79.	0.4	94
592	Laparoscopic versus open retroperitoneal lymph node dissection: a cost analysis. <i>Journal of Urology</i> , 2002, 168, 1945-9; discussion 1949.	0.4	11
593	Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: a decision analytical approach. <i>Journal of Urology</i> , 2002, 167, 75-9.	0.4	20
594	Management of ureteral calculi: a cost comparison and decision making analysis. <i>Journal of Urology</i> , 2002, 167, 1621-9.	0.4	52

#	ARTICLE	IF	CITATIONS
595	Differential Expression of Nuclear Retinoid Receptors in Normal and Malignant Prostates. Journal of Clinical Oncology, 2000, 18, 116-116.	1.6	73